<p>Progyny, Inc. ((PGNY)) 已召开其第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Progyny 最近的财报电话会议传达了明显的积极基调，管理层强调了创纪录的第一季度收入、扩大的利润率和强劲的现金生成，同时完成了股份回购。尽管承认存在行政清理工作、更高的资本支出和来自转型客户的可比性噪音，管理层将这些视为可控的逆风，背景是需求的韧性和临床结果的验证。</p>
<h2>创纪录的第一季度收入和利润超预期</h2>
<p>Progyny 报告的第一季度收入达到了指导范围的高端，尽管同比增长仅为 1.4%，但仍显示出强劲的需求。排除一位处于转型护理协议下的大客户，收入增长超过 12%，净收入、每股收益和调整后的 EBITDA 均超出管理层的指导范围。</p>
<h2>上调全年盈利目标</h2>
<p>公司上调了调整后 EBITDA、净收入和每股收益的全年指导，表明对盈利持久性的信心，即使在持续投资的情况下。管理层现在预计调整后 EBITDA 在 2.32 亿至 2.44 亿美元之间，净收入在 1.037 亿至 1.123 亿美元之间，稀释每股收益在 1.23 至 1.34 美元之间，调整后的每股收益指导为 1.98 至 2.09 美元。</p>
<h2>收入展望受转型逆风影响</h2>
<p>对于第二季度，Progyny 指导收入范围为 3.42 亿至 3.55 亿美元，意味着报告增长为 2.7% 至 6.6%，但在调整 1720 万美元的转型客户后，增速为 8.3% 至 12.4%。全年收入预计在 13.65 亿至 14.05 亿美元之间，转化为 5.9% 至 9.0% 的增长，或在剔除转型收入后为 10.1% 至 13.3%。</p>
<h2>健康的利用率和会员参与度</h2>
<p>管理层强调，会员参与度保持强劲，利用率趋向于公司历史范围的高端。公司保持全年利用率假设不变，预计在 1.04% 至 1.05% 之间，并维持每位女性独特的 ART 周期消费在 0.93 至 0.95 之间，表明基础活动没有明显放缓。</p>
<h2>利润率扩张和韧性盈利能力</h2>
<p>毛利率在本季度有所扩大，调整后的 EBITDA 利润率保持在健康水平，即使 Progyny 加大了对其平台和服务的投资。高管指出，运营效率和较低的股票薪酬是利润率提升的关键因素，并表示这些好处预计将持续并支持持续盈利能力。</p>
<h2>强劲的现金生成和无债务资产负债表</h2>
<p>公司继续将盈利转化为现金，在过去一段时间内产生了约 4.46 亿美元的经营现金流，并强调了强大的营运资金管理。Progyny 在季度末拥有 2.25 亿美元的现金、现金等价物和可交易证券，总营运资金为 2.66 亿美元，未动用的 2 亿美元循环信贷额度，且资产负债表上没有债务。</p>
<h2>完成股份回购和资本回报策略</h2>
<p>Progyny 通过在本季度回购超过 550 万股，花费约 1.16 亿美元，积极进行资本回报，完成了 2 亿美元的授权。总共约 880 万股被注销，董事会现在正在评估潜在的新回购计划，表明继续愿意将多余资本返还给股东。</p>
<h2>销售管道势头和降低风险的续约</h2>
<p>销售管道和早期客户承诺的进展远超去年，强化了公司到 2026 年的增长前景。Progyny 最大客户的一些早期积极续约决定将续约风险降低到本周期的最低水平，额外的势头来自渠道合作伙伴和支持 Progyny Select 产品的聚合商。</p>
<h2>第三方研究验证临床和成本效益</h2>
<p>一项大型客户的长期分析显示，Progyny 的项目提供了更多与生育相关的怀孕，治疗的怀孕有效性翻倍，并在八年内减少了多胎和流产。研究还发现，早产率减少了一半以上，平均每个婴儿的成本和 NICU 费用下降，进一步强化了 Progyny 对雇主和会员的价值主张。</p>
<h2>转型客户影响头条比较</h2>
<p>管理层提醒投资者，处于转型护理安排下的一位大型前客户（将于 2025 年中期结束）正在造成同比比较中的噪音，并抑制报告增长。第一季度的 1.4% 收入增长在排除该客户后超过 12%，强调头条放缓反映的是可比性效应，而非核心需求的减弱。</p>
<h2>增加资本支出和持续投资压力</h2>
<p>Progyny 正在故意提升其投资水平，第一季度资本支出达到 630 万美元，比去年增加 350 万美元，因为它正在构建新的平台能力和会员功能。这些投资对短期自由现金的部署产生了适度压力，但被视为维持竞争差异化和长期增长的关键。</p>
<h2>行政调整和资格补救</h2>
<p>公司承认，过去的行政资格调整在被覆盖的生命数量上造成了意外，增加了报告结果的变动性。为了解决这个问题，Progyny 正在努力在年底之前从大多数客户那里获取完整的资格文件，旨在减少运营噪音并随着时间的推移提高预测准确性。</p>
<h2>对潜在参与变动的保守态度</h2>
<p>尽管参与度和利用率仍然强劲，但管理层故意在历史范围的低端维持保守假设，以应对未来潜在的变动。这种谨慎的姿态旨在缓冲成员活动和治疗模式的意外变化，否则可能会对结果造成压力。</p>
<h2>投资者认知与估值压力</h2>
<p>高管指出，一些投资者正在考虑可能的需求变化和更广泛的担忧，如与人工智能相关的劳动力市场变化，尽管这些压力在当前运营中并不明显。这种基本面与情绪之间的差距已成为估值压力，管理层强调持续的执行是缩小这种脱节的主要工具。</p>
<h2>Progyny Select 的延迟收入</h2>
<p>Progyny Select 继续受到聚合商和渠道合作伙伴的积极接纳和关注，支持其作为增长向量的角色。然而，公司警告称，由于小型雇主的标准采购和续约周期，该产品的收入贡献将在年内后期偏向，限制了其对报告的顶线增长的短期影响。</p>
<h2>指导要点与前景</h2>
<p>展望未来，Progyny 预计第二季度收入为 3.42 亿至 3.55 亿美元，调整后的 EBITDA 为 5800 万至 6200 万美元，净收入为 2580 万至 2870 万美元，GAAP 每股收益为 0.31 至 0.35 美元。对于全年，管理层的目标是收入为 13.65 亿至 14.05 亿美元，调整后的 EBITDA 为 2.32 亿至 2.44 亿美元，GAAP 每股收益在 1.23 至 1.34 美元之间，同时假设利用率指标稳定和 ART 周期消费平稳。</p>
<p>Progyny 的财报电话会议描绘了一幅公司在投资与纪律之间取得平衡的图景，强劲的利润率、现金流和健康的资产负债表抵消了与过渡相关的表面噪音和行政清理工作。随着盈利指导的上调、强劲的项目活动以及对其临床和成本优势的独立验证，该公司正将自己定位为生育福利领域的持久增长故事，即使它承认并计划应对参与度和投资者情绪的潜在波动。</p>

PGNY

<p>Progyny, Inc. 报告了创纪录的第一季度收入，超出预期，同比增长 1.4%，并提高了全年盈利目标。调整后的 EBITDA 预计在 2.32 亿至 2.44 亿美元之间，净收入和每股收益也有所增加。公司强调了强劲的会员参与度和现金生成能力，季度末无债务，现金余额为 2.25 亿美元。Progyny 完成了 2 亿美元的股票回购，并正在评估新的回购计划。尽管受到过渡客户的影响，销售管道显示出积极的势头，第三方研究验证了 Progyny 方案的有效性</p>

<p>Progyny, Inc. ((PGNY)) has held its Q1 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Progyny, Inc. ((PGNY)) 已召开其第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Progyny’s latest earnings call struck a decidedly constructive tone as management highlighted record first-quarter revenue, expanded margins, and strong cash generation alongside a fully executed share buyback. While acknowledging administrative clean‑up work, higher CapEx, and comparability noise from a transition client, executives framed these as manageable headwinds against a backdrop of resilient demand and validated clinical outcomes.</p>
<div class="lb-trans"><p>Progyny 最近的财报电话会议传达了明显的积极基调，管理层强调了创纪录的第一季度收入、扩大的利润率和强劲的现金生成，同时完成了股份回购。尽管承认存在行政清理工作、更高的资本支出和来自转型客户的可比性噪音，管理层将这些视为可控的逆风，背景是需求的韧性和临床结果的验证。</p>
</div><h2>Record Q1 Revenue and Profit Beat</h2>
<div class="lb-trans"><h2>创纪录的第一季度收入和利润超预期</h2>
</div><p>Progyny reported record first-quarter revenue at the high end of guidance, underscoring solid demand despite modest headline growth of 1.4% year over year. Excluding a large client under a transition-of-care agreement, revenue grew more than 12%, and net income, EPS, and adjusted EBITDA all exceeded management’s guidance ranges.</p>
<div class="lb-trans"><p>Progyny 报告的第一季度收入达到了指导范围的高端，尽管同比增长仅为 1.4%，但仍显示出强劲的需求。排除一位处于转型护理协议下的大客户，收入增长超过 12%，净收入、每股收益和调整后的 EBITDA 均超出管理层的指导范围。</p>
</div><h2>Raised Full-Year Profitability Targets</h2>
<div class="lb-trans"><h2>上调全年盈利目标</h2>
</div><p>The company raised full-year guidance for adjusted EBITDA, net income, and EPS, signaling confidence in earnings durability even as it continues to invest. Management now expects adjusted EBITDA between $232 million and $244 million, net income of $103.7 million to $112.3 million, and diluted EPS of $1.23 to $1.34, with adjusted EPS guided to $1.98 to $2.09.</p>
<div class="lb-trans"><p>公司上调了调整后 EBITDA、净收入和每股收益的全年指导，表明对盈利持久性的信心，即使在持续投资的情况下。管理层现在预计调整后 EBITDA 在 2.32 亿至 2.44 亿美元之间，净收入在 1.037 亿至 1.123 亿美元之间，稀释每股收益在 1.23 至 1.34 美元之间，调整后的每股收益指导为 1.98 至 2.09 美元。</p>
</div><h2>Revenue Outlook Masked by Transition Headwinds</h2>
<div class="lb-trans"><h2>收入展望受转型逆风影响</h2>
</div><p>For the second quarter, Progyny guided revenue to a range of $342 million to $355 million, implying reported growth of 2.7% to 6.6% but a faster 8.3% to 12.4% pace when adjusting for the $17.2 million transition client. Full-year revenue is projected between $1.365 billion and $1.405 billion, translating to 5.9% to 9.0% growth, or 10.1% to 13.3% once transition revenue is stripped out.</p>
<div class="lb-trans"><p>对于第二季度，Progyny 指导收入范围为 3.42 亿至 3.55 亿美元，意味着报告增长为 2.7% 至 6.6%，但在调整 1720 万美元的转型客户后，增速为 8.3% 至 12.4%。全年收入预计在 13.65 亿至 14.05 亿美元之间，转化为 5.9% 至 9.0% 的增长，或在剔除转型收入后为 10.1% 至 13.3%。</p>
</div><h2>Healthy Utilization and Member Engagement</h2>
<div class="lb-trans"><h2>健康的利用率和会员参与度</h2>
</div><p>Management emphasized that member engagement remained robust, with utilization trending toward the high end of the firm’s historical range. The company kept its full-year utilization assumptions intact at 1.04% to 1.05% and maintained expected ART cycle consumption per female unique between 0.93 and 0.95, suggesting no evident slowdown in underlying activity.</p>
<div class="lb-trans"><p>管理层强调，会员参与度保持强劲，利用率趋向于公司历史范围的高端。公司保持全年利用率假设不变，预计在 1.04% 至 1.05% 之间，并维持每位女性独特的 ART 周期消费在 0.93 至 0.95 之间，表明基础活动没有明显放缓。</p>
</div><h2>Margin Expansion and Resilient Profitability</h2>
<div class="lb-trans"><h2>利润率扩张和韧性盈利能力</h2>
</div><p>Gross margin expanded in the quarter, and adjusted EBITDA margin held at healthy levels even as Progyny stepped up investments in its platform and services. Executives cited operational efficiencies and lower stock-based compensation as key contributors to margin gains, noting that these benefits are expected to recur and support ongoing profitability.</p>
<div class="lb-trans"><p>毛利率在本季度有所扩大，调整后的 EBITDA 利润率保持在健康水平，即使 Progyny 加大了对其平台和服务的投资。高管指出，运营效率和较低的股票薪酬是利润率提升的关键因素，并表示这些好处预计将持续并支持持续盈利能力。</p>
</div><h2>Robust Cash Generation and Debt-Free Balance Sheet</h2>
<div class="lb-trans"><h2>强劲的现金生成和无债务资产负债表</h2>
</div><p>The company continued to convert earnings into cash, generating roughly $446 million in operating cash flow over the trailing period and highlighting strong working capital discipline. Progyny ended the quarter with $225 million in cash, cash equivalents, and marketable securities, total working capital of $266 million, an undrawn $200 million revolver, and no debt on the balance sheet.</p>
<div class="lb-trans"><p>公司继续将盈利转化为现金，在过去一段时间内产生了约 4.46 亿美元的经营现金流，并强调了强大的营运资金管理。Progyny 在季度末拥有 2.25 亿美元的现金、现金等价物和可交易证券，总营运资金为 2.66 亿美元，未动用的 2 亿美元循环信贷额度，且资产负债表上没有债务。</p>
</div><h2>Completed Share Buyback and Capital Return Strategy</h2>
<div class="lb-trans"><h2>完成股份回购和资本回报策略</h2>
</div><p>Progyny leaned into capital returns by repurchasing more than 5.5 million shares for about $116 million during the quarter, completing its $200 million authorization. In total, around 8.8 million shares were retired, and the board is now evaluating a potential new repurchase program, signaling continued willingness to return excess capital to shareholders.</p>
<div class="lb-trans"><p>Progyny 通过在本季度回购超过 550 万股，花费约 1.16 亿美元，积极进行资本回报，完成了 2 亿美元的授权。总共约 880 万股被注销，董事会现在正在评估潜在的新回购计划，表明继续愿意将多余资本返还给股东。</p>
</div><h2>Sales Pipeline Momentum and De-Risked Renewals</h2>
<div class="lb-trans"><h2>销售管道势头和降低风险的续约</h2>
</div><p>The sales pipeline and early client commitments are tracking substantially ahead of last year, reinforcing the company’s growth runway into 2026. Early positive renewal decisions from some of Progyny’s largest clients have reduced renewal risk to its lowest level at this point in the cycle, with additional momentum coming from channel partnerships and aggregators supporting the Progyny Select offering.</p>
<div class="lb-trans"><p>销售管道和早期客户承诺的进展远超去年，强化了公司到 2026 年的增长前景。Progyny 最大客户的一些早期积极续约决定将续约风险降低到本周期的最低水平，额外的势头来自渠道合作伙伴和支持 Progyny Select 产品的聚合商。</p>
</div><h2>Third-Party Study Validates Clinical and Cost Benefits</h2>
<div class="lb-trans"><h2>第三方研究验证临床和成本效益</h2>
</div><p>A long-term analysis by a large client showed that Progyny’s programs delivered more fertility-related pregnancies, doubled pregnancy effectiveness per treatment, and reduced multiple births and miscarriages over an eight-year period. The study also found that preterm delivery rates were more than halved and that average cost per baby and NICU expenses declined, reinforcing Progyny’s value proposition for both employers and members.</p>
<div class="lb-trans"><p>一项大型客户的长期分析显示，Progyny 的项目提供了更多与生育相关的怀孕，治疗的怀孕有效性翻倍，并在八年内减少了多胎和流产。研究还发现，早产率减少了一半以上，平均每个婴儿的成本和 NICU 费用下降，进一步强化了 Progyny 对雇主和会员的价值主张。</p>
</div><h2>Transition Client Skews Headline Comparisons</h2>
<div class="lb-trans"><h2>转型客户影响头条比较</h2>
</div><p>Management reminded investors that a large former client under a transition-of-care arrangement, ending mid-2025, is creating noise in year-over-year comparisons and muting reported growth. The first quarter’s modest 1.4% revenue gain becomes more than 12% when that client is excluded, underscoring that the headline slowdown reflects comparability effects rather than weakening core demand.</p>
<div class="lb-trans"><p>管理层提醒投资者，处于转型护理安排下的一位大型前客户（将于 2025 年中期结束）正在造成同比比较中的噪音，并抑制报告增长。第一季度的 1.4% 收入增长在排除该客户后超过 12%，强调头条放缓反映的是可比性效应，而非核心需求的减弱。</p>
</div><h2>Increased CapEx and Ongoing Investment Pressure</h2>
<div class="lb-trans"><h2>增加资本支出和持续投资压力</h2>
</div><p>Progyny is deliberately lifting its investment profile, with first-quarter capital expenditures reaching $6.3 million, up $3.5 million from a year earlier, as it builds new platform capabilities and member features. These investments weigh modestly on near-term free cash deployment but are framed as critical to sustaining competitive differentiation and long-term growth.</p>
<div class="lb-trans"><p>Progyny 正在故意提升其投资水平，第一季度资本支出达到 630 万美元，比去年增加 350 万美元，因为它正在构建新的平台能力和会员功能。这些投资对短期自由现金的部署产生了适度压力，但被视为维持竞争差异化和长期增长的关键。</p>
</div><h2>Administrative True-Ups and Eligibility Remediation</h2>
<div class="lb-trans"><h2>行政调整和资格补救</h2>
</div><p>The company acknowledged that past administrative eligibility true-ups had created surprises in the number of covered lives, adding variability to reported results. To address this, Progyny is working to secure full eligibility files from a majority of clients by year-end, aiming to reduce operational noise and improve forecasting accuracy over time.</p>
<div class="lb-trans"><p>公司承认，过去的行政资格调整在被覆盖的生命数量上造成了意外，增加了报告结果的变动性。为了解决这个问题，Progyny 正在努力在年底之前从大多数客户那里获取完整的资格文件，旨在减少运营噪音并随着时间的推移提高预测准确性。</p>
</div><h2>Conservative Stance on Potential Engagement Variability</h2>
<div class="lb-trans"><h2>对潜在参与变动的保守态度</h2>
</div><p>Although engagement and utilization remain strong, management is deliberately maintaining conservative assumptions at the low end of historical ranges to account for potential future variability. This cautious posture is designed to buffer against unexpected shifts in member activity and treatment patterns that could otherwise pressure results.</p>
<div class="lb-trans"><p>尽管参与度和利用率仍然强劲，但管理层故意在历史范围的低端维持保守假设，以应对未来潜在的变动。这种谨慎的姿态旨在缓冲成员活动和治疗模式的意外变化，否则可能会对结果造成压力。</p>
</div><h2>Investor Perception and Valuation Overhangs</h2>
<div class="lb-trans"><h2>投资者认知与估值压力</h2>
</div><p>Executives noted that some investors are pricing in headline risks around possible demand shifts and broader concerns such as AI-related labor market changes, even though these pressures are not evident in current operations. This gap between fundamentals and sentiment has become a valuation overhang, with management emphasizing ongoing execution as the primary tool to narrow that disconnect.</p>
<div class="lb-trans"><p>高管指出，一些投资者正在考虑可能的需求变化和更广泛的担忧，如与人工智能相关的劳动力市场变化，尽管这些压力在当前运营中并不明显。这种基本面与情绪之间的差距已成为估值压力，管理层强调持续的执行是缩小这种脱节的主要工具。</p>
</div><h2>Delayed Revenue from Progyny Select</h2>
<div class="lb-trans"><h2>Progyny Select 的延迟收入</h2>
</div><p>Progyny Select continues to see favorable reception and interest from aggregators and channel partners, supporting its role as a growth vector. However, the company cautioned that revenue contributions from this offering will skew later in the year because of standard buying and renewal cycles for smaller employers, limiting its near-term impact on reported top-line growth.</p>
<div class="lb-trans"><p>Progyny Select 继续受到聚合商和渠道合作伙伴的积极接纳和关注，支持其作为增长向量的角色。然而，公司警告称，由于小型雇主的标准采购和续约周期，该产品的收入贡献将在年内后期偏向，限制了其对报告的顶线增长的短期影响。</p>
</div><h2>Guidance Highlights and Outlook</h2>
<div class="lb-trans"><h2>指导要点与前景</h2>
</div><p>Looking ahead, Progyny projects second-quarter revenue of $342 million to $355 million and adjusted EBITDA of $58 million to $62 million, with net income of $25.8 million to $28.7 million and GAAP EPS of $0.31 to $0.35. For the full year, management is targeting revenue of $1.365 billion to $1.405 billion, adjusted EBITDA of $232 million to $244 million, and GAAP EPS between $1.23 and $1.34, while assuming stable utilization metrics and steady ART cycle consumption.</p>
<div class="lb-trans"><p>展望未来，Progyny 预计第二季度收入为 3.42 亿至 3.55 亿美元，调整后的 EBITDA 为 5800 万至 6200 万美元，净收入为 2580 万至 2870 万美元，GAAP 每股收益为 0.31 至 0.35 美元。对于全年，管理层的目标是收入为 13.65 亿至 14.05 亿美元，调整后的 EBITDA 为 2.32 亿至 2.44 亿美元，GAAP 每股收益在 1.23 至 1.34 美元之间，同时假设利用率指标稳定和 ART 周期消费平稳。</p>
</div><p>Progyny’s earnings call painted a picture of a company balancing investment with discipline, as strong margins, cash flow, and a clean balance sheet offset transition-related headline noise and administrative clean-up work. With raised profitability guidance, robust pipeline activity, and independent validation of its clinical and cost advantages, the firm is positioning itself as a durable growth story in fertility benefits even as it acknowledges and plans for potential volatility in engagement and investor sentiment.</p>
<div class="lb-trans"><p>Progyny 的财报电话会议描绘了一幅公司在投资与纪律之间取得平衡的图景，强劲的利润率、现金流和健康的资产负债表抵消了与过渡相关的表面噪音和行政清理工作。随着盈利指导的上调、强劲的项目活动以及对其临床和成本优势的独立验证，该公司正将自己定位为生育福利领域的持久增长故事，即使它承认并计划应对参与度和投资者情绪的潜在波动。</p>
</div>

Progyny 的财报电话会议传达了自信且盈利的增长信号